Development asset linked to Kunming Hope of in public FDA and regional records.
pharma · Elderly AML Patients · Menkes Syndrome
Kunming Hope of
Kunming Hope of Health Hospital
Kunming Hope of drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 8
- Patents
- 0
Kunming Hope of pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kunming Hope of drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Kunming Hope of in public FDA and regional records.
-
Development asset linked to Kunming Hope of in public FDA and regional records.
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
Development asset linked to Kunming Hope of in public FDA and regional records.
-
Development asset linked to Kunming Hope of in public FDA and regional records.
-
sorafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Kunming Hope of's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor